Cancer treatment delivered with RenovoCath®. Consider the PanTheR study.

The PanTheR study (NCT06805461) was set up to collect safety information and treatment outcomes for patients who receive oncology treatment for solid tumor cancers using the RenovoCath® targeted therapeutic device.

Participants must meet the following enrollment criteria:

Have been diagnosed with solid tumor cancers and are aged at least 18 years at the time of their first procedure
Are willing to provide informed consent and HIPAA release for use of their relevant medical records

This study is observational, and you may not receive any direct benefit from participating. However, the information gathered may help improve the understanding of the long-term safety and effectiveness of RenovoCath®, potentially benefiting future patients.

Your email address

First name

Last name

Date of birth

Street address and number

City

State

Zip Code

Phone Number

Preferred Payment Method

Please provide the information below for your next of kin

Full Name

Phone Number

Email Address

Relationship

You will first complete this registration form.
You will be guided to electronically sign the informed consent and HIPAA release form
Once you sign the above documents, you will receive a payment card with the allocated stipend either electronically or by mail, as per your indicated preference.
The study team will review your medical records for the purposes of the study. No further action will be required on your part.

PanTheR: A Registry Study in Patients Treated for Solid Tumor Cancers Using the RenovoCath® Targeted Therapeutic Device